Melanoma News and Research

Latest Melanoma News and Research

Folic acid and vitamin B12 lower homocysteine levels in patients who experience heart attack: JAMA

Patients who had experienced a heart attack and lowered their blood homocysteine levels with folic acid and vitamin B12 supplementation did not have an associated lower risk of heart attack, coronary death or stroke, according to a study in the June 23/30 issue of JAMA. However, the researchers did find that folic acid supplementation did not increase the risk of cancer, which has been speculated.

23 Jun 2010

Michigan State University researchers analyze histiocytic sarcomas

Michigan State University veterinarians are taking part in a two-year, $5.3 million project to analyze five cancers in dogs, research that could offer new insight into canine cancer genes and their potential impact on the human form of the disease.

22 Jun 2010

Pfizer to discontinue commercial availability of Mylotarg for AML in U.S.

Pfizer Inc. announced today that based on discussions with the U.S. Food and Drug Administration (FDA), it will be discontinuing commercial availability of Mylotarg® (gemtuzumab ozogamicin for Injection) (used for the treatment of relapsed acute myeloid leukemia (AML)) in the United States and that it will be voluntarily withdrawing the new drug application (NDA) for Mylotarg effective October 15, 2010.

22 Jun 2010

OXiGENE reports encouraging data from ZYBRESTAT program at Glaucoma and Retinopathies 2010 conference

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that the company presented an update on its ZYBRESTAT ophthalmology program, including encouraging preclinical data showing that the company's topical formulation achieved target retina/choroid concentrations with minimal systemic exposure.

22 Jun 2010

Exelixis announces regaining of rights to develop and commercialize XL184

Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.

21 Jun 2010

Prototype drug blocks MCL-1 protein that helps tumors survive treatment: Scientists

Scientists at Dana-Farber Cancer Institute have found a way to disable a common protein that often thwarts chemotherapy treatment of several major forms of cancer.

21 Jun 2010

Neupro improves wellbeing impaired by pain related to Restless Legs Syndrome

The first data to show that Neupro® (rotigotine transdermal system) significantly improved wellbeing and daily activities that are often impaired by pain related to Restless Legs Syndrome (RLS) were presented this week at the 14th International Congress of Parkinson's Disease and Movement Disorders in Buenos Aires, Argentina.

18 Jun 2010

Protect Your Lungs, LUNGevity Foundation announce merger

To combat the nation's number one cancer killer, non-profit organizations Protect Your Lungs and LUNGevity Foundation today announced they will join forces in an effort to fund research and hope for a cure for lung cancer. Together, the new organization hopes to create the same successful improvements for lung cancer mortality rates as those experienced by breast, prostate, and colon cancer. The merged organization, committed to elevating lung cancer on the national agenda, will operate under the name LUNGevity Foundation with offices in Washington, D.C. and Chicago.

18 Jun 2010

VCU researchers discover mechanism that regulates gene expression and growth in melanoma cells

Virginia Commonwealth University researchers have discovered a mechanism by which an enzyme regulates gene expression and growth in melanoma cells, a finding that could someday lead to more effective drugs to attack cancers and make them more treatable.

18 Jun 2010

RG7204 holds promise for metastatic melanoma with V600E BRAF mutation

Preclinical findings recently published in Cancer Research, a journal of the American Association for Cancer Research, showed RG7204 (PLX4032) inhibited proliferation of tumor cell lines that expressed V600E-BRAF, a mutation found in several human cancers, including melanoma.

16 Jun 2010

Identification of key player in signaling pathway offers hope for new targeted melanoma therapies

Identification of a key player in a signaling pathway involved in the development of melanoma - the deadliest form of skin cancer - may offer hope for new targeted melanoma therapies.

16 Jun 2010

Independent SMB recommends continuance of Allovectin-7 Phase 3 trial for metastatic melanoma

Vical Incorporated today announced that an independent Safety Monitoring Board (SMB) for the company's Phase 3 trial of Allovectin-7® in patients with metastatic melanoma has completed the trial's fourth scheduled safety analysis and recommended that the trial continue per the protocol.

16 Jun 2010

Study validates Grm1 protein as target for melanoma treatment

Research by investigators at The Cancer Institute of New Jersey (CINJ) is showing new promise in the treatment of melanoma, the most serious of skin cancers. The findings, published in the May 27, 2010, online edition of the Journal of Investigative Dermatology further validate the team's clinical and pre-clinical findings that blocking the signaling normally activated by a receptor called Grm1 results in decreased cell growth and decreased migration of melanoma cells, confirming that Grm1 is a potential target for the treatment of melanoma.

16 Jun 2010

Combination of BRAF-targeted therapy and immunotherapy shows promise for treatment of melanoma

Combined targeted therapy against the BRAF/MAPK pathway with immunotherapy shows promise as a new therapeutic approach for the treatment of melanoma, according to results of a preclinical study published in Cancer Research, a journal of the American Association for Cancer Research.

16 Jun 2010

First patient treated in multicentre Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine for melanoma

Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, today announces the enrolment and treatment of the first patient in its multicentre Phase I clinical trial of SCIB1, its DNA ImmunoBody® vaccine being developed for the treatment of melanoma. The trial will evaluate the safety and tolerability of SCIB1 in patients with late stage melanoma.

15 Jun 2010

Study: Millions of cancer survivors put off care they can't afford

The Associated Press: A new study says about 2 million of the 12 million cancer survivors in the United States put off medical care because they cannot afford it. "The study is being called the first to estimate how often current and former patients have skipped getting care because of money worries. It was led by Kathryn Weaver, a researcher at Wake Forest University Baptist Medical Center in Winston-Salem, N.C.

15 Jun 2010

Abstract on Phase I/II DIGNITY trial of ThermoDox in RCW Breast Cancer accepted at ASTRO 2010

Celsion Corporation announced today that an abstract on the Phase I/II DIGNITY trial of ThermoDox in Recurrent Chest Wall Breast Cancer has been accepted for a poster session at the 52nd American Society for Radiation Oncology Annual Meeting. The abstract will provide updated clinical results, as well as the rationale and design of the DIGNITY study, which is evaluating ThermoDox in combination with microwave hyperthermia in women with RCW Breast Cancer.

14 Jun 2010

Report highlights deprivation gap caused by late diagnosis of cancer, differences in treatment choices

There could be as many as 14,000 fewer cases of cancer each year in England if everyone was as healthy as the richest 20 per cent in the country. And the difference between the classes is more marked among men than women. Among men there were 21 per cent more cases of cancer in the most deprived areas compared to the least deprived, whereas the gap among women was 11 per cent.

14 Jun 2010

Delcath Systems to host conference call to update shareholders about recent progress

Delcath Systems, Inc. a development stage, specialty pharmaceutical and medical device company focused on oncology will host a conference call to discuss recent corporate developments on Tuesday, June 15, 2010 at 4:30 p.m., Eastern. Eamonn P. Hobbs, the Company's President and CEO, David McDonald, CFO, and Krishna Kandarpa, MD, Chief Medical Officer, will be on hand during the call and webcast.

11 Jun 2010

Abraxis BioScience presents phase 3 trial data on metastatic malignant melanoma

Abraxis BioScience, Inc. presented trial design information from its ongoing phase 3 registration trial of nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension), in melanoma, an aggressive form of skin cancer that affects more than 68,000 people in the U.S. each year.

11 Jun 2010

Melanoma News and Research

Latest Melanoma News and Research

Folic acid and vitamin B12 lower homocysteine levels in patients who experience heart attack: JAMA

Michigan State University researchers analyze histiocytic sarcomas

Pfizer to discontinue commercial availability of Mylotarg for AML in U.S.

OXiGENE reports encouraging data from ZYBRESTAT program at Glaucoma and Retinopathies 2010 conference

Exelixis announces regaining of rights to develop and commercialize XL184

Prototype drug blocks MCL-1 protein that helps tumors survive treatment: Scientists

Neupro improves wellbeing impaired by pain related to Restless Legs Syndrome

Protect Your Lungs, LUNGevity Foundation announce merger

VCU researchers discover mechanism that regulates gene expression and growth in melanoma cells

RG7204 holds promise for metastatic melanoma with V600E BRAF mutation

Identification of key player in signaling pathway offers hope for new targeted melanoma therapies

Independent SMB recommends continuance of Allovectin-7 Phase 3 trial for metastatic melanoma

Study validates Grm1 protein as target for melanoma treatment

Combination of BRAF-targeted therapy and immunotherapy shows promise for treatment of melanoma

First patient treated in multicentre Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine for melanoma

Study: Millions of cancer survivors put off care they can't afford

Abstract on Phase I/II DIGNITY trial of ThermoDox in RCW Breast Cancer accepted at ASTRO 2010

Report highlights deprivation gap caused by late diagnosis of cancer, differences in treatment choices

Delcath Systems to host conference call to update shareholders about recent progress

Abraxis BioScience presents phase 3 trial data on metastatic malignant melanoma

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Melanoma News and Research

Latest Melanoma News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in